Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Eagle Pharmaceuticals Inc EGRX

Healthcare Biotechnology
Eagle Pharmaceuticals, Inc. is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial capabilities. The Company is focused on developing medicines that result in improvements in patients' lives. The Company's commercialized products include vasopressin, PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO and BARHEMSYS... see more

Recent & Breaking News (NDAQ:EGRX)

Lifshitz Law PLLC Announces Investigations of Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX), Akero Therapeutics, Inc. (NASDAQ: AKRO), Rivian Automotive, Inc. (NASDAQ: RIVN), and QuidelOrtho Corporation (NASDAQ: QDEL)

Accesswire 9 days ago

Lifshitz Law PLLC Announces Investigations of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX), Driven Brands Holdings Inc. (NASDAQ:DRVN), Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), and Gristone bio, Inc. (NASDAQ:GRTS)

Accesswire June 14, 2024

Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq

GlobeNewswire May 22, 2024

Lifshitz Law PLLC Announces Investigations of Cummins Inc. (NYSE:CMI), Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX), Fox Factory Holding Corp. (NASDAQ:FOXF), and Inspire Medical Systems, Inc. (NYSE:INSP)

Accesswire May 17, 2024

Eagle Pharmaceuticals Announces a Trial in Progress Presentation of Phase 2/3 Study of Intravenous Amisulpride as Prevention of Postoperative Nausea and Vomiting in Pediatric Patients at the Upcoming Society for Ambulatory Anesthesia (SAMBA) 2024 Annual Meeting

GlobeNewswire April 30, 2024

Lifshitz Law PLLC Announces Investigations of InMode Ltd. (NASDAQ: INMD), General Motors Company (NYSE: GM), Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX), and Driven Brands Holdings Inc. (NASDAQ: DRVN)

Accesswire April 17, 2024

Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida

GlobeNewswire April 15, 2024

Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K

GlobeNewswire April 12, 2024

Lifshitz Law PLLC Announces Investigations of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX), ON Semiconductor Corporation (NASDAQ:ON), Mercury Systems, Inc. (NASDAQ:MRCY), and The Lovesac Company (NASDAQ:LOVE)

Accesswire April 5, 2024

EAGLE PHARMACEUTICALS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their Options

PR Newswire February 9, 2024

Levi & Korsinsky Reminds Eagle Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 9, 2024 - EGRX

Accesswire February 9, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Eagle Pharmaceuticals, Inc. - EGRX

Newsfile February 9, 2024

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Newsfile February 9, 2024

EGRX DEADLINE TODAY: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important February 9 Deadline in Securities Class Action - EGRX

Newsfile February 9, 2024

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 9, 2024 in Eagle Pharmaceuticals, Inc. Lawsuit - EGRX

Accesswire February 9, 2024

EGRX FINAL DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Eagle Pharmaceuticals, Inc. Shareholders of Final Hours to Join Class Action!

Accesswire February 9, 2024

Eagle Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 9, 2024 to Discuss Your Rights - EGRX

PR Newswire February 9, 2024

Shareholders of Eagle Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before February 9, 2024 to Discuss Your Rights - EGRX

Accesswire February 9, 2024

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Accesswire February 9, 2024

Shareholders that lost money on Eagle Pharmaceuticals, Inc. (EGRX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

Accesswire February 8, 2024